Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add filters








Language
Year range
1.
Chinese Journal of Preventive Medicine ; (12): 311-314, 2002.
Article in Chinese | WPRIM | ID: wpr-257270

ABSTRACT

<p><b>OBJECTIVE</b>Inhibition of acetylcholinesterase (AChE) in human brain caused by phoxim or phoxim oxon, their reactivation with oxime and aging of phosphorylated AChE were studied and compared in vitro.</p><p><b>METHODS</b>Micro-colorispectrophotometric assay was used to determine the activity of AChE.</p><p><b>RESULTS</b>The pI(50) of inhibition of AChE in human brain by phoxim and phoxim oxon were 5.39 and 5.77, respectively, whereas the pI(90) were 4.60 and 5.00, respectively. The reactivation rate of 0.1 mmol/L of pralidoxime (2-PAM), obidoxime (LüH(6)), trimedoxime (TMB-4) and pyramidoxime (HI-6) for phoxim-inhibited AChE in human brain was 65%, 97%, 91% and 56%, respectively, and their reactivation rate for phoxim oxon-inhibited AChE in human brain was 97%, 87%, 99% and 89%, respectively. The optimal reactivator for phoxim and phoxim oxon-inhibited AChEs was LüH(6) and TMB-4, respectively. The half aging time of phoxim and phoxim oxon inhibited phosphorylated AChEs were 39 and 28 hours, respectively, and the 99% aging time were 256 and 186 hours, respectively.</p><p><b>CONCLUSIONS</b>LüH(6) or TMB-4 should be used at the earlier as possible after poisoning with phoxim and phoxim oxon, and the reactivator should be consecutively used for more than seven days, even after their acute symptoms have been well controlled.</p>


Subject(s)
Humans , Acetylcholinesterase , Metabolism , Brain , Cholinesterase Inhibitors , Pharmacology , Cholinesterase Reactivators , Pharmacology , Enzyme Stability , In Vitro Techniques , Obidoxime Chloride , Pharmacology , Organothiophosphorus Compounds , Pharmacology , Oximes , Pharmacology , Paraoxon , Pharmacology , Pralidoxime Compounds , Pharmacology , Time Factors , Trimedoxime , Pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL